StockData

Garmin vs Northrop Grumman

GRMN and NOC side by side, both in measuring, analyzing, and controlling instruments; photographic, medical and optical goods; watches and clocks. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GRMN and NOC compare

Northrop Grumman is the larger company, worth 1.5 times as much as Garmin ($79.2B against $52.6B).

On earnings, Northrop Grumman is cheaper: it trades at 17.7× trailing earnings, against 28.1× for Garmin.

Garmin grew revenue faster over the last twelve months (13.5% versus 5.9% for Northrop Grumman).

Garmin keeps more of each dollar of sales as profit, with a net margin of 24.5% compared with 10.5% at Northrop Grumman.

Both pay dividends: Garmin yields 1.4% and Northrop Grumman 1.7%.

Garmin scores higher on the StockData Score (22 against 18 for Northrop Grumman), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGRMNNOC
Size and price
Market cap$52.6B$79.2B
Share price$272.67$557.54
Change, 1 year24.2%−4.7%
Change, 5 years91.8%53.0%
Beta (5Y)0.970.29
Employees6,50095K
StockData Score
Total score22 (better)18
Valuation score13 (better)
Growth score6 (better)2
Performance score6 (better)5
Health score6 (better)4
Dividend score34 (better)
Valuation
P/E28.1×17.7× (better)
P/S6.9×1.8× (better)
P/B5.8×4.4× (better)
EV/EBITDA23.6×15.0× (better)
P/FCF32.9×21.7× (better)
PEG1.45–
FCF yield3.0%4.6% (better)
Fair value$247.45$647.15
Margin of safety−10.2%13.8% (better)
Growth
Revenue growth (TTM)13.5% (better)5.9%
Revenue growth, 5Y average11.6% (better)2.7%
Net income growth (TTM)19.7% (better)14.0%
EPS growth (TTM)19.8% (better)16.0%
EPS growth, 5Y average10.7% (better)8.9%
Profitability
Gross margin60.1%–
Operating margin27.6% (better)10.7%
Net margin24.5% (better)10.5%
FCF margin20.9% (better)8.5%
Return on equity21.9%27.0% (better)
Return on invested capital29.5% (better)13.1%
Financial health
Debt / equity0.000.85 (better)
Net debt / EBITDA–2.10
Current ratio3.03 (better)1.17
Altman Z-score15.77 (better)3.13
Piotroski F-score7 (better)6
Dividends and buybacks
Dividend yield1.4%1.7% (better)
Payout ratio38.5%29.9%
Years of dividend growth–16
Dividend growth, 5Y average–9.7%
Buyback yield–1.0%
Shareholder yield1.4%2.7% (better)
Ownership
Held by institutions57.1%83.5%
Held by insiders17.4%0.22%
Insider net buying, 12 months−$20.0M (better)−$26.4M
Superinvestors holding–1
Short interest, % of float2.1%1.6%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.